NasdaqCM:CLDXBiotechs
Celldex Therapeutics (CLDX) Stock Looks Rich On Book Value But Strong On Returns
Celldex Therapeutics stock has more than doubled over the past year, yet the latest valuation checks and market multiples suggest the shares lean expensive rather than clearly cheap.
The 101.9% return over the past year highlights how strongly sentiment has shifted toward Celldex Therapeutics, which raises the bar for what the current price can justify.
Progress in Celldex Therapeutics' barzolvolimab and CDX-622 programs can support expectations for future growth. However, trial setbacks or...